Information  X 
Enter a valid email address

Syncona portfolio company Nighstar books loss; starts new clinical trial

By BFN News | 07:41 AM | Tuesday 13 November, 2018

Life sciences company investor Syncona noted that portfolio company Nightstar Therapeutics had booked a third-quarter net loss owing to increased R&D spending. Nightstar, which develops treatments for rare inherited retinal diseases, also said it had kicked off a new clinical trail. Its net losses for the three months through September were $7.6m, narrowing from a loss of $8.2m on-year. R&D spending rose to $7.8m, up from $4.0m. The new phase 2/3 expansion study was designed to be consistent with recommendations in the FDA's draft guidance on the development of gene therapy products for retinal disorders. It would evaluate the safety and efficacy of a treatment in patients with a diagnosis of XLRP due to RPGR mutations, as confirmed by genetic testing. Story provided by

a d v e r t i s e m e n t